Compare Incyte Corporation (INCY) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Mercadolibre Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Mercadolibre Inc trades at $1,889.85 (market cap $94.13B). The key difference: Mercadolibre Inc is far larger — about 4.1× Incyte Corporation's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Mercadolibre Inc for 117 Days on average.
| INCY | MELI | |
|---|---|---|
Market Cap | $22.85B | $94.13B |
Volume | 1,927,029 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $2.36K |
52-Week Low | $83.80 | $1.55K |
Typical Hold Time | 33 Days | 117 Days |
Enterprise Value | $18.35B | $101.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
MercadoLibre (MELI) trades at $1,856.66, down 0.86% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $28.89 billion in 2025, though net income margins dipped to 6.91%. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy business growth, while its fintech credit portfolio surged 75% in Q2 2026 to $16.4 billion.
Outlook remains positive with analyst consensus at 'Buy' and a $2,170 price target, but risks include profit margin pressure and macroeconomic headwinds in Latin America. The stock's high P/E of 50.51 suggests growth expectations are priced in, requiring sustained execution to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
